Protirelin
Thypinone, Thyrel (protirelin) is a protein pharmaceutical. Protirelin was first approved as Thypinone on 1982-01-01. The pharmaceutical is active against thyrotropin-releasing hormone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Protirelin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| THYPINONE | Abbott Biotherapeutics | N-017638 DISCN | 1982-01-01 | 1 products |
| THYREL TRH | Ferring Pharmaceuticals | N-018087 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| thryotropin releasing hormone | unapproved drug other | 2012-06-19 |
| thyrotropin releasing hormone | unapproved drug other | 2012-06-19 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2725 | Injection, protirelin, per 250 mcg |
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fertilization in vitro | D005307 | — | — | — | — | — | 2 | — | 2 |
| Oocyte donation | D018587 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spinocerebellar degenerations | D013132 | — | G11 | — | 3 | 4 | — | — | 7 |
| Spinocerebellar ataxias | D020754 | — | — | — | 2 | 4 | — | — | 6 |
| Infertility | D007246 | EFO_0000545 | — | — | 1 | 2 | — | 1 | 4 |
| Ovulation induction | D010062 | — | — | — | 1 | 1 | — | — | 2 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | 1 | — | 1 | 2 |
| Newborn respiratory distress syndrome | D012127 | — | P22 | — | — | 1 | — | 1 | 2 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thyroid diseases | D013959 | — | E00-E07 | — | 2 | — | — | 2 | 4 |
| Healthy volunteers/patients | — | — | — | 2 | 1 | — | — | 1 | 4 |
| Pituitary diseases | D010900 | — | E23.7 | — | 1 | — | — | 1 | 2 |
| Goiter | D006042 | EFO_0004283 | E04.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | — | — | — | — | 1 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypothyroidism | D007037 | EFO_0004705 | E03.9 | — | — | — | — | 2 | 2 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Laron syndrome | D046150 | Orphanet_633 | E34.321 | — | — | — | — | 1 | 1 |
| Chromosome aberrations | D002869 | Orphanet_68335 | — | — | — | — | — | 1 | 1 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 1 | 1 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | — | — | — | 1 | 1 |
| Neuroendocrine carcinoma | D018278 | — | — | — | — | — | — | 1 | 1 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 1 | 1 |
| Acute kidney injury | D058186 | — | N17 | — | — | — | — | 1 | 1 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Protirelin |
| INN | protirelin |
| Description | Protirelin is a tripeptide composed of L-pyroglutamyl, L-histidyl and L-prolinamide residues joined in sequence. It has a role as a human metabolite. It is a peptide hormone and a tripeptide. |
| Classification | Peptide |
| Drug class | prehormones or hormone-release stimulating peptides: thyrotropin releasing hormone analogues |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1 |
Identifiers
| PDB | — |
| CAS-ID | 24305-27-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1472 |
| ChEBI ID | 35940 |
| PubChem CID | — |
| DrugBank | DB09421 |
| UNII ID | 5Y5F15120W (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,620 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
20 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use